期刊
BIOMARKERS IN MEDICINE
卷 3, 期 3, 页码 289-306出版社
FUTURE MEDICINE LTD
DOI: 10.2217/BMM.09.15
关键词
anticancer treatment; cancer biomarkers; choline metabolism; quantitative metabolomics; signal transduction inhibitor; Warburg effect
资金
- NIH [R21 CA108624, P30 CA046934]
Cancer cells possess a highly unique metabolic phenotype, which is characterized by high glucose uptake, increased glycolytic activity, decreased mitochondrial activity, low bioenergetic and increased phospholipid turnover. These metabolic hallmarks can be readily assessed by metabolic technologies - either in vitro or in vivo - to monitor responsiveness and resistance to novel targeted drugs, where specific inhibition of cell proliferation (cytostatic effect) occurs rather than direct induction of cell death (cytotoxicity). Using modern analytical technologies in combination with statistical approaches, 'metabolomics', a global metabolic profile on patient samples can be established and validated for responders and nonresponders, providing additional metabolic end points. Discovered metabolic end points should be translated into noninvasive metabolic imaging protocols.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据